Health Care – Page 35 – The Media Pub News ™

Bristol Myers Squibb and bluebird bio announce submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for adults with relapsed and refractory multiple myeloma

July 30, 2020

BLA submission based on results from pivotal Phase 2 KarMMa study evaluating ide-cel in heavily pre-treated patient population Companies are committed to working with the FDA to rapidly advance ide-cel through the regulatory review process PRINCETON, N.J., & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BLUE #BMS—Bristol

Business, Health Care

Daiichi Sankyo and AstraZeneca enter new global development and commercialization collaboration for Daiichi Sankyo’s ADC DS-1062

July 27, 2020

Agreement represents second collaboration between Daiichi Sankyo and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC) AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5

Business, Health Care

LabVantage COVID-19 LIMS solution implemented for onsite workplace health and safety

July 22, 2020

—Leading Consumer Goods Company Offers Employee Health Testing at In-House Test Centers— SOMERSET, N.J.–(BUSINESS WIRE)–#COVID–LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services including purpose-built LIMS solutions that allow labs to go live faster and at a lower total

Business, Health Care

Bayer continues to earn top marks in 2020 Disability Equality Index

July 20, 2020

Company earns score of 90 and recognized as a Best Place to Work for Disability Inclusion WHIPPANY, N.J.–(BUSINESS WIRE)–For the second consecutive year, Bayer U.S. was recognized as a Best Place to Work for Disability Inclusion, earning a score of 90 in

Health Care

European Medicines Agency validates Bristol Myers Squibb’s application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)

July 17, 2020

MAA is for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B Application based on positive results from TRANSCEND NHL 001 study and additional TRANSCEND WORLD 001 study PRINCETON, N.J.–(BUSINESS

Business, Health Care

Humanigen expands partnership with Catalent biologics to manufacture investigational COVID-19 therapeutic candidate lenzilumab

July 16, 2020

Humanigen’s investigational monoclonal antibody, lenzilumab, was developed using Catalent’s proprietary GPEx® cell line development technology Expanded partnership established product supply for lenzilumab, an investigational Phase 3 product for COVID-19 Catalent’s OneBio® integrated biologics suite expected to accelerate development, manufacturing and supply of

Health Care, Local News

Bristol Myers Squibb announces expiration and final results of Registered Exchange Offers

July 16, 2020

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb”) announced today the expiration and final results of its offers to exchange (the “Registered Exchange Offers”) any and all of its outstanding (i) $19,000,000,000 aggregate principal amount of senior unsecured notes previously issued

Health Care, Local News

FDA grants priority review to Merck’s New Drug Application for Vericiguat

July 16, 2020

Application Based on First Contemporary Outcomes Study Focused Exclusively on Chronic Heart Failure Patient Population Following a Worsening Event KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug